Last reviewed · How we verify
Betametasone (BETAMETHASONE)
Betametasone (generic name: BETAMETHASONE) is a Corticosteroid drug. It is currently FDA-approved (first approved 1961) for Corticosteroid-responsive dermatoses.
Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system.
Betametasone is a small molecule modality. It has been studied as an intervention for chronic low-back pain in clinical trials, including those comparing echo-guided and non-echo-guided infiltration.
At a glance
| Generic name | BETAMETHASONE |
|---|---|
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 1961 |
Mechanism of action
Think of it like a key fitting into a lock. Betamethasone is the key that fits into the glucocorticoid receptor, which is like a lock on a cell. When the key fits in, it turns on a series of signals inside the cell that help to calm down the immune system and reduce inflammation.
Approved indications
- Corticosteroid-responsive dermatoses
Common side effects
- Premature baby
- Premature delivery
- Low birth weight baby
- Foetal exposure during pregnancy
- Maternal exposure during pregnancy
- Appendicolith
- Normal labour
- Neonatal respiratory distress syndrome
- Appendicitis
- Macular degeneration
- Patent ductus arteriosus
- Foetal growth restriction
Drug interactions
- aripiprazole
- edrophonium
- neostigmine
- pyridostigmine
- quetiapine
- rifabutin
- rifampicin
- rifapentine
- risperidone
- warfarin
Key clinical trials
- Capsular Distension Versus Corticosteroid Injection in Adhesive Capsulitis (NA)
- Clinical Trial to Demonstrate That the Dual Laser Therapy is Effective for the Treatment of Vulvar Lichen Sclerosus (NA)
- Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (PHASE2)
- Comparative Bioavailability Study Between Etoricoxib / Betamethasone Administered Individually or in Combination (PHASE1)
- A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects With Acute Gouty Arthritis (PHASE2)
- Betamethasone and Severity of Hyaline Membrane Disease
- Clinical Trial to Evaluate the Efficacy and Safety of Platelet-rich Plasma Infiltration in Chronic Omalgia (PHASE3)
- Evaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Psoriasis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Betametasone CI brief — competitive landscape report
- Betametasone updates RSS · CI watch RSS
Frequently asked questions about Betametasone
What is Betametasone?
How does Betametasone work?
What is Betametasone used for?
What is the generic name of Betametasone?
What drug class is Betametasone in?
When was Betametasone approved?
What development phase is Betametasone in?
What are the side effects of Betametasone?
What does Betametasone target?
Related
- Drug class: All Corticosteroid drugs
- Target: All drugs targeting Glucocorticoid receptor
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Corticosteroid-responsive dermatoses
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing